 |
 |
Scientific Program
Chairperson: Roy Silverstein (US)
| Protection from Cardiovascular Disease: Getting to the Heart of the Matter | PL-MO-001 |
| Helen H. Hobbs (US) | 9:45 – 10:30 AM |
Chairperson: Mary Cushman (US)
| Thromboprophylaxis as a key patient safety priority: Current approaches and future directions | PL-MO-002 |
| William H. Geerts (CA) | 5:15 - 6:00 PM |
Chairpersons: Phillip Wells (CA) and Samuel Goldhaber (US)
| Short term prognosis of pulmonary embolism | SA-MO-001 |
| Drahomir Aujesky (CH) | 11:00 - 11:30 AM |
| Treatment strategies including thrombolysis | |
| and embolectomy | SA-MO-002 |
| Samuel Goldhaber (US) | 11:30 - 12:00 PM |
| Diagnostic management of pulmonary embolism | SA-MO-003 |
| Menno Huisman (NL) | 12:00 - 12:30 PM |
Chairpersons: Kenneth Kanushansky (US) and Joseph Italiano (US)
| Empirical and theoretical phenotypic | |
| discrimination in hemostasis | SA-MO-004 |
| Kathleen Brummel-Ziedins (US) | 11:00 - 11:30 AM |
| Systems biology of platelets and coagulation | SA-MO-005 |
| Scott Diamond (US) | 11:30 - 12:00 PM |
| Selective sorting of platelet ?-granule contents | SA-MO-006 |
| Joseph Italiano (US) | 12:00 - 12:30 PM |
Chairpersons: Robert Montgomery (US) and Cécile Dennis (FR)
| Reduced von Willebrand factor survival in von | |
|---|---|
| Willebrand disease: Pathophysiological | |
| and clinical relevance | SA-MO-007 |
| Giancarlo Castaman (IT) | 11:00 - 11:30 AM |
| Mouse models of von Willebrand disease | SA-MO-008 |
| Cécile Denis (FR) | 11:30 - 12:00 PM |
| Genotype/phenotype association in von Willebrand | |
| disease: Is the glass half full or half empty? | SA-MO-009 |
| David Lillicrap (CA) | 12:00 - 12:30 PM |
Chairpersons: Charles Esmon (US) and Hartmut Weiler (US)
| Critical roles for thrombin in acute and chronic | |
|---|---|
| inflammation | SA-MO-010 |
| Anthony Dorling (UK) | 11:00 - 11:30 AM |
| Dendritic cells and PAR signaling in Inflammation | SA-MO-011 |
| Wolfram Ruf (US) | 11:30 - 12:00 PM |
| Modulation of sepsis with activated protein C variants | SA-MO-012 |
| Hartmut Weiler (US) | 12:00 - 12:30 PM |
Chairpersons: Christel Van Geet (BE) and Charles Abrams (US)
| Altered megakaryopoiesis in Type IIb von | |
| Willebrand disease | SA-MO-013 |
| Alan Nurden (FR) | 11:00 - 11:30 AM |
| Regulation of platelets biogenesis | SA-MO-014 |
| Ramesh Shivdasani (US) | 11:30 - 12:00 PM |
| Lesions in platelet signaling | SA-MO-015 |
| Christel Van Geet (BE) | 12:00 - 12:30 PM |
Chairpersons: William Aird (US) and Susan Smyth (US)
| Systems approach to inflammation resolution: Identification of novel anti-inflammatory and pro-resolving lipid mediators | SA-MO-016 |
| Charles N. Serhan (US) | 11:00 - 11:30 AM |
Molecular control of angiogenesis and remodeling |
SA-MO-017 |
| William Sessa (US) | 11:30 - 12:00 PM |
| Regulation of vascular cell function by bioactive l ysolipids | SA-MO-018 |
| Susan Smyth (US) | 12:00 - 12:30 PM |
Abstract Symposia consist of an invited speaker and four highly rated abstracts presented on a related general theme
Chairperson: Saskia Middeldorp (NL)
| Thrombophilia testing in asymptomatic family members: | |
| More harm than good? | AS-MO-001 |
| Saskia Middeldorp (NL) | 2:15 - 2:45 PM |
2:45 - 3:00 PM
A PROSPECTIVE COHORT STUDY ON THE ABSOLUTE RISK OF VENOUS THROMBOEMBOLISM IN ASYMPTOMATIC SUBJECTS WITH HEREDITARY DEFICIENCIES OF PROTEIN S, PROTEIN C OR ANTITHROMBIN
B. K. Mahmoodi* (NL), J. Brouwer, M. ten Kate, W. Lijfering, N. Veeger, H. Kluin-Nelemans, J. van der Meer
AS-MO-003
3:00 - 3:15 PM
MORTALITY IN THROMBOPHILIA: A CONTROLLED EVALUATION FROM THE EUROPEAN PROSPECTIVE COHORT ON THROMBOPHILIA (EPCOT)
I. Pabinger* (AT), C. Y. Vossen, J. Lang, J. Conard, C. García-Dabrio, W. Miesbach, G. Palareti, P. Svensson, A. Kaider, F. R. Rosendaal
AS-MO-004
3:15- 3:30 PM
RISK OF RECURRENCE AMONG HETEROZYGOUS CARRIERS OF FACTOR II (FII) G20210A AND A FIRST UNPROVOKED VENOUS THROMBOEMBOLISM (VTE)
G. Hron* (AT), L. Eischer, S. Eichinger, P. A. Kyrle
AS-MO-005
3:30 - 3:45 PM
MULTIPLE SNP TESTING TO PREDICT RISK OF FIRST VENOUS THROMBOSIS
I. D. Bezemer* (NL), C. J. M. Doggen, S. Le Cessie, P. H. Reitsma, L. A. Bare, F. R. Rosendaal
| Chairperson: Thomas Wakefield (US) | |
|---|---|
| Aggressive therapies for DVT | AS-MO-006 |
| Thomas Wakefield (US) | 2:15 - 2:45 PM |
AS-MO-007
2:45 - 3:00 PM
ADDITIONAL CATHETER-DIRECTED VENOUS THROMBOLYSIS IN ILIOFEMORAL DEEP VEIN THROMBOSIS; SHORT-TERM RESULTS FROM THE CAVENT STUDY, A MULTIleft, RANDOMIZED CONTROLLED TRIAL
T. R. Enden* (NO), C. E. Slagsvold, N. E. Kløw, P. M. Sandset
AS-MO-008
3:00 - 3:15 PM
ILIOFEMORAL VENOUS THROMBOSIS SUCCESSFULLY TREATED WITH CATHETER-DIRECTED THROMBOLYSIS
M. Jørgensen* (DK), S. Just, R. Broholm, N. Bækgaard, L. Panduro
AS-MO-009
3:15 - 3:30 PM
THE PAVIA ENDARTERECTOMY PROGRAM FOR THE MANAGEMENT OF PULMONARY ENDARTERECTOMY (PEA) IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH)
F. Piovella* (IT), A. M. D’Armini, M. Barone, V. Emmi, C. Beltrametti, M. Viganò
AS-MO-010
3:30 - 3:45 PM
CLINICAL SAFETY, EFFICACY & PHARMACOKINETICS OF INTRA-CLOT TPA FOR LOWER EXTREMITY DVT
J. N. Lozier* (US), R. Chang
| Chairperson: Jo’se Lo’pez (US) | |
|---|---|
| ADAMTS13, TTP and related disorders | AS-MO-011 |
| Jose Lopez (US) | 2:15 - 2:45 PM |
AS-MO-012
2:45 - 3:00 PM
CRYSTAL STRUCTURE OF THE EXOSITES-CONTAINING FRAGMENT OF ADAMTS13
M. Akiyama* (JP), S. Takeda, K. Kokame, J. Takagi, T. Miyata
AS-MO-013
3:00 - 3:15 PM
MOLECULAR MODELLING OF ADAMTS-13 METALLOPROTEINASE DOMAIN
R. de Cristofaro* (IT), S. Lancellotti, N. Pozzi, V. de Filippis
AS-MO-014
3:15 - 3:30 PM
UNPRODUCTIVE BINDING OF ADAMTS13 TO VON WILLEBRAND FACTOR
H. B. Feys* (BE), P. J. Anderson, K. Vanhoorelbeke, J. E. Sadler
AS-MO-015
3:30 - 3:45 PM
AMINO ACID RESIDUES R660, R661 AND Y662 WITHIN THE SPACER DOMAIN OF ADAMTS13 ARE ESSENTIAL FOR RECOGNITION AND CLEAVAGE OF VON WILLEBRAND FACTOR
S. Jin* (US), X. Zheng
| Chairperson: Peter Lenting (NL) | |
|---|---|
| Biology of von Willebrand factor | AS-MO-016 |
| Peter Lenting (NL) | 2:15 - 2:45 PM |
2:45 - 3:00 PM
CLEARANCE OF VON WILLEBRAND FACTOR (VWF) IN TYPE 2 VON WILLEBRAND DISEASE (VWD): THE IMPLICATIONS OF VWF PROPEPTIDE (VWFPP) AND VWF:AG LEVELS
S. L. Haberichter* (US), G. Castaman, P. D. James, P. A. Christopherson, F. Roheghiero, D. Lillicrap, R. R. Montgomery, for Canadian Vicenza and ZPMCB-VWD Study Groups
AS-MO-018
3:00 - 3:15 PM
EXPRESSION OF HUMAN TYPE 2B VON WILLEBRAND DISEASE MUTANTS IN THE VWF KO MOUSE MODEL M. Golder* (CA), C. M. Pruss, C. Hegadorn, K. Laverty, K. Sponagle, D. Lillicrap
AS-MO-019
3:15 - 3:30 PM
ASSOCIATIONS BETWEEN THE VON WILLEBRAND FACTOR GENE (VWF) VARIANT C.2771G>A (P.R924Q), VON WILLEBRAND FACTOR ANTIGEN (VWF:AG) AND FVIII ACTIVITY (FVIII:C) LEVELS AND ITS ROLE AS A RISK FACTOR FOR TYPE 1 VON WILLEBRAND DISEASE (VWD)
N. Hickson* (UK), D. J. Hampshire, P. R. Winship, P. D. James, I. R. Peake, A. C. Goodeve, on behalf of the EUVWD and ZPMCB-VWD Study Groups
AS-MO-020
3:30 - 3:45 PM
THE IMPACT OF VON WILLEBRAND FACTOR SEQUENCE CHANGES THAT AFFECT ADAMTS13MEDIATED CLEAVAGE IN THE VWF KNOCKOUT MOUSE MODEL
C. M. Pruss* (CA), M. Golder, C. Hegadorn, K. Laverty, K. Sponagle, C. Notley, Y. Chirinian, D. Lillicrap
| Chairperson: George Broze (US) | |
|---|---|
| Protein Z and ZPI: An update | AS-MO-021 |
| George Broze (US) | 2:15 - 2:45 PM |
AS-MO-022
2:45 - 3:00 PM
ACTIVATED PROTEIN C (APC) INHIBITS INFLAMMATION AND APOPTOSIS BY REGULATING ENDOPLASMIC RETICULUM (ER) STRESS
L. J. Toltl* (CA), R. C. Austin, P. C. Y. Liaw
AS-MO-023
3:00 - 3:15 PM
CRYSTAL STRUCTURES SHOW HOW PROTEIN Z CATALYSES ZPI INHIBITION OF FXa ON PHOSPHOLIPID SURFACES
Z. Wei, Y. Yan, A. Zhou* (UK)
AS-MO-024
3:15 - 3:30 PM
PLATELET TISSUE FACTOR PATHWAY INHIBITOR (TFPI) PREVENTS HEPATIC AND CEREBRAL FIBRIN DEPOSITION IN MOUSE TISSUES AND LIMITS THROMBUS GROWTH
S. A. Maroney* (US), J. P. Ferrel, B. C. Cooley, A. E. Mast
AS-MO-025
3:30 - 3:45 PM
MECHANISMS OF COFACTOR-ASSISTED PROTEASE INHIBITION BY PROTEIN C INHIBITOR
W. Li* (UK), J. A. Huntington
| Chairperson: Rezan Kadir (UK) | |
|---|---|
| Women and bleeding disorders: New perspectives | AS-MO-026 |
| Rezan Kadir (UK) | 2:15 - 2:45 PM |
AS-MO-027
2:45 - 3:00 PM
INITIAL DEPLOYMENT OF A COMPREHENSIVE, ONTOLOGY-BACKED, WEB-BASED BLEEDING HISTORY PHENOTYPING INSTRUMENT IN NORMAL INDIVIDUALS
A. C. Mauer* (US), E. M. Barbour, N. A. Khazanov, N. Levenkova, S. A. Mollah, B. S. Coller
AS-MO-028
3:00 - 3:15 PM
ESTABLISHMENT OF A EUROPEAN NETWORK OF RARE BLEEDING DISORDERS (EN-RBD DATABASE): PRELIMINARY RESULTS ON 190 PATIENTS
M. Menegatti* (IT), R. Palla, S. M. Siboni, M. Benedik-Dolnicar, C. Bidlingmaier, T. Celkan, P. Giangrande, R. Gilmore, J. Ingerslev, K. Peerlink, H. Pergantou, F. Suzan, M. Spreafico, R. Waha, P. Lanzi, F. Peyvandi
AS-MO-029
3:15 - 3:30 PM
PREGNANCY AND DELIVERY IN WOMEN WITH VON WILLEBRAND DISEASE AND DIFFERENT VON WILLEBRAND FACTOR MUTATIONS
G. Castaman* (IT), A. Tosetto, F. Rodeghiero
AS-MO-030
3:30 - 3:45 PM
RISK OF POSTPARTUM HEMORRHAGE IN WOMEN RECEIVING THERAPEUTIC DOSES OF LOWMOLECULAR-WEIGHT HEPARIN
S. Roshani* (NL), D. M. Cohn, A. Stehouwer, S. Hamers, H. Wolf, J. M. van der Post, H. R. Büller, P. W. Kamphuisen, S. Middeldorp
| Chairperson: Jerry Ware (US) | |
|---|---|
| The platelet paradigm in cancer | AS-MO-031 |
| Jerry Ware (US) | 2:15 - 2:45 PM |
AS-MO-032
2:45 - 3:00 PM
THE EFFECT OF P2Y-MEDIATED ACTIVATION ON VEGF AND ENDOSTATIN RELEASE FROM PLATELETS
N. M. Bambace* (US), J. E. Levis, C. E. Holmes
AS-MO-033
3:00 - 3:15 PM
AN ASSOCIATION BETWEEN ANTI-PLATELET DRUG USE AND REDUCED CANCER PREVALENCE IN DIABETIC PATIENTS: RESULTS FROM THE VERMONT DIABETES INFORMATION SYSTEM C. E. Holmes* (US), M. E. Ramos-Nino, B. Littenberg
AS-MO-034
3:15 - 3:30 PM
GENETIC VARIANTS OF PLATELET FUNCTION AND CANCER MORTALITY: A FOLLOW-UP STUDY
J. D. Snoep* (NL), C. E. Holmes, F. R. Rosendaal, J. G. van der Bom
AS-MO-035
3:30 - 3:45 PM
PLASMA LEVELS OF MICROPARTICLE ASSOCIATED TISSUE FACTOR ACTIVITY IN PATIENTS WITH CLINICALLY SUSPECTED PULMONARY EMBOLISM WITH OR WITHOUT CANCER
P. Garcia Rodriguez* (NL), H. C. J. Eikenboom, M. E. T. Tesselaar, M. V. Huisman, M. Nijkeuter, S. Osanto, R. M. Bertina
| Chairperson: Angel Garcia (ES) | |
|---|---|
| Novel strategies in platelet research: The proteomics approach | AS-MO-036 |
| Angel Garcia, (ES) | 2:15 - 2:45 PM |
AS-MO-037
2:45 - 3:00 PM
DEFINING THE FUNCTION OF NOVEL PLATELET GENES USING A LASER THROMBOSIS MODEL IN DANIO RERIO
I. I. Salles* (BE), M. N. O’Connor, A. Cvejic, N. A. Watkins, P. Burns, A. Walker, S. F. Garner, C. I. Jones, I. C. Macaulay, M. Steward, J. Zwaginga, S. L. Bray, F. Dudbridge, B. de Bono, A. H. Goodall, H. Deckmyn, D. L. Stemple, W. H. Ouwehand, on behalf of the Bloodomics consortium
AS-MO-038
3:00 - 3:15 PM
THE IDENTIFICATION OF ABI-1 AS NEW VASP EVH1 DOMAIN INTERACTING PARTNER IN HUMAN PLATELETS BASED ON THE “PLATELETWEB” KNOWLEDGE BASE
M. Dittrich, V. Strassberger, T. Jarchau, P. Tas, U. Lewandrowski, T. Dandekar, U. Walter, I. Birschmann* (DE)
AS-MO-039
3:15 - 3:30 PM
STUDY OF BIMOLECULAR INTEGRIN-FIBRINOGEN INTERACTIONS UNDER A CONSTANT UNBINDING FORCE
R. I. Litvinov* (US), H. Shuman, J. W. Weisel, J. S. Bennett
AS-MO-040
3:30 - 3:45 PM
RAPID ADHESION KINETICS OF PLATELETS UNDER VERY HIGH SHEAR
D. N. Ku* (US), A. N. Para, D. L. Bark
| Chairperson: Diego Mezzano (CL) | |
|---|---|
| Regulation of platelet-expressed tissue factor | AS-MO-041 |
| Diego Mezzano (CL) | 2:15 - 2:45 PM |
AS-MO-042
2:45 - 3:00 PM
CELLULAR SOURCES OF TISSUE FACTOR THAT CONTRIBUTE TO ACTIVATION OF COAGULATION IN ENDOTOXEMIC MICE
R. Pawlinski* (US), N. Mackman
AS-MO-043
3:00 - 3:15 PM
ENDOTHELIAL TISSUE FACTOR CONTRIBUTES TO FIBRIN GENERATION DURING THROMBUS FORMATION IN LIVING MICE SUBJECTED TO LASER INJURY
V. M. Chen* (US), T. H. David, G. Merrill-Skoloff, N. Mackman, S. R. Coughlin, B. C. Furie, B. Furie
AS-MO-044
3:15 - 3:30 PM
LEVELS OF MICROPARTICLE TISSUE FACTOR ACTIVITY CORRELATE WITH COAGULATION ACTIVATION IN ENDOTOXEMIC MICE
J. Wang* (US), D. Manly, D. Kirchhofer, R. Pawlinski, N. Mackman
AS-MO-045
3:30 - 3:45 PM
INHIBITION OF PROTEIN DISULPHIDE ISOMERASE ON ENDOTHELIAL CELLS ENHANCES COAGULATION THROUGH PHOSPHATIDYLSERINE EXPOSURE
N. I. Popescu* (US), C. Lupu, F. Lupu
| Chairperson: Mark Ginsberg (US) | |
|---|---|
| Dynamic regulation of cell-cell adhesion | AS-MO-046 |
| Mark Ginsberg (US) | 2:15 - 2:45 PM |
2:45 - 3:00 PM
SEROTONIN STIMULATES PLATELET RECEPTOR SHEDDING BY TUMOR NECROSIS FACTORALPHA-CONVERTING ENZYME (ADAM17)
D. Duerschmied* (US), M. Canault, D. Lievens, A. Brill, S. Cifuni, M. Bader, D. D. Wagner
AS-MO-048
3:00 - 3:15 PM
CADHERIN 6 MODULATES PLATELET FUNCTION THROUGH INTEGRIN αIIBβ3
E. Dunne* (IE), M. C. Berndt, D. J. Kenny
AS-MO-049
3:15 - 3:30 PM
TARGETING ONGOING ARTERIAL THROMBOSIS WITH PLATELET-SPECIFIC MICROPARTICLES
Z. M. Ruggeri* (US), J. N. Orje, B. Molins, S. Harvey, S. Mitragorti, J. Smith
AS-MO-050
3:30 - 3:45 PM
GI24R: A NOVEL MEMBER OF IMMUNOGLOBULIN RECEPTOR ON PLATELETS
U. J. H. Sachs, S. Jessen, B. Kehrel, K. Clemetson, S. Santoso* (DE)
| Chairperson: Sherrill Slichter (US) | |
|---|---|
| Current advances in platelet transfusion therapy | AS-MO-051 |
| Sherrill Slichter (US) | 2:15 - 2:45 PM |
AS-MO-052
2:45 - 3:00 PM
MODIFIED MONOCLONAL PLATELET ANTIBODIES PREVENT ANTIBODY-MEDIATED CLEARANCE OF HUMAN PLATELETS IN AN IN VIVO MODEL OF IMMUNE THROMBOCYTOPENIA T. Bakchoul* (DE), B. Boylan, G. Bein, S. Santoso, P. J. Newman
AS-MO-053
3:00 - 3:15 PM
THE ALPHA2 INTEGRIN (GPIA) POLYMORPHISM: THE NEW PLATELET ALLOANTIGEN CABA AND 6 NEW MUTATIONS
G. Bertrand* (FR), V. Jallu, D. Saillant, D. Kervran, C. Martageix, C. Kaplan
AS-MO-054
3:15 - 3:30 PM
ASSESSMENT OF GENOTYPE-PHENOTYPE RELATIONSHIP FOR SIX COMMON PLATELET POLYMORPHISMS IN 286 HEALTHY SUBJECTS
C. Martínez, A. I. Antón, J. Corral, T. Quiroga, O. Panes, M. L. Lozano, R. González-Conejero, R. Teruel, L. Navarro-Núñez, J. Pereira, N. Navarro, D. Mezzano, V. Vicente, J. Rivera* (ES)
AS-MO-055
3:30 - 3:45 PM
A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (RAISE) OF ELTROMBOPAG FOR THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
G. Cheng, M. N. Saleh, J. B. Bussel* (US), C. Marcher, S. Vasey, B. Mayer, M. Aivado, M. Arning, N. L. Stone
| Chairperson: Ulrich Von Andrian (US) | |
|---|---|
| Mechanisms and consequences of dendritic | AS-MO-056 |
| cell migration | |
| Ulrich Von Andrian (US) | 2:15 - 2:45 PM |
AS-MO-057
2:45 - 3:00 PM
PECAM-1 POLYMORPHISM IN IG DOMAIN 6 (S536N) PLAYS A ROLE IN TRANSENDOTHELIAL MIGRATION OF NEUTROPHILS
B. Bayat* (DE), S. Werth, C. Andrei-Selmer, P. Newman, S. Santoso
AS-MO-058
3:00 - 3:15 PM
A ROLE OF THE ENDOTHELIAL P2Y1 RECEPTOR IN MONOCYTE ADHESION TO AND TRANSMIGRATION ACROSS MURINE MICROVASCULAR ENDOTHELIAL CELLS IN VITRO
M. Zerr-Fouineau* (FR), B. Hechler, I. Lanois, J. Cazenave, C. Gachet
AS-MO-059
3:15 - 3:30 PM
HYPERCOAGULABILITY PROMOTES PLAQUE STABILITY DURING ATHEROGENESIS BY INHIBITING MONOCYTE MIGRATION THROUGH A PAR-1, PLC-BETA, PI3K, AND NO-DEPENDENT MECHANISM
K. Shahzad, S. Seehaus, I. Vinnikov, H. Wang, M. Kashif, M. Thati, P. P. Nawroth, B. Isermann* (DE)
AS-MO-060
3:30 - 3:45 PM
CD146 AND ITS SOLUBLE FORM REGULATE MONOCYTE TRANSENDOTHELIAL MIGRATION
N. Bardin* (FR), M. Blot-Chabaud, N. Despoix, A. Kebir, K. Harhouri, F. Vely, F. Dignat George
| Chairperson: Holger Gerhardt (UK) | |
|---|---|
| Molecular control of angiogenic sprouting | AS-MO-061 |
| Holger Gerhardt (UK) | 2:15 - 2:45 PM |
AS-MO-062
2:45 - 3:00 PM
VITRONECTIN PROMOTES ISCHEMIA-INDUCED ANGIOGENESIS
J. Wu* (US), W. P. Fay
AS-MO-063
3:00 - 3:15 PM
ALTERNATIVELY SPLICED TISSUE FACTOR PROMOTES ANGIOGENESIS THROUGH INTEGRIN LIGATION
Y. W. van den Berg* (NL), L. G. van den Hengel, H. R. Myers, O. Ayachi, K. (JO)ova, W. Ruf, A. C. Spek, P. H. Reitsma, H. H. Versteeg
AS-MO-064
3:15 - 3:30 PM
ANGIOGENIC SIGNALING BY RAP1B IN ENDOTHELIAL CELLS INVOLVES ACTIVATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 AND INTEGRIN ALPHAV/BETA3 M. Chrzanowska-Wodnicka* (US)
AS-MO-065
3:30 - 3:45 PM
IDENTIFICATION OF UPREGULATED PROANGIOGENIC GENES IN INTIMAL NEOVESSELS FROM HUMAN ADVANCED ATHEROSCLEROTIC PLAQUES USING LASER-CAPTURE MICROSCOPE M. M. Turu* (ES), L. Badimon, A. Luque, M. Baldellou, N. Rovira, J. Krupinski, M. Slevin